Clinical Trial Update: Hyperimmune Bovine Colostrum - TRAVELAN™ for Patients With Chronic Hepatitis C Virus Infection Not Responding to Standard Therapy [Phase 1]

View source ↗

Summary

Phase 1 trial of TRAVELAN (hyperimmune bovine colostrum) for asymptomatic chronic hepatitis C carriers not responding to standard therapy has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• Travelan (IMM-124E)

Snippet

Sponsor: Hadassah Medical Organization | Conditions: Asymptomatic Chronic HCV Carriers | Phase 1 | Status: WITHDRAWN